← back to search

Shrinivas Bishu

Perrigo (United States) · US
Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Gut microbiota and health, and Colorectal Cancer Screening and Detection.
h-index
34
citations
3,816
works
194
NIH funding
primary concept
Medicine
email

Recent publications

Review Article: TL1A Inhibitors in IBD - Mechanistic Rationale and Clinical Evidence.
2026cited by 0position: contributordoi
The role of gastrointestinal PCR in inflammatory bowel disease flares: A double-edged sword or a diagnostic breakthrough?
2026cited by 0position: contributordoi
Nociplastic Pain is Associated With Increased Healthcare Utilization and Lower Quality of Life in Patients With Inflammatory Bowel Disease.
2026cited by 0position: contributordoi
Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis.
2026cited by 0position: contributordoi
Gut Microbiota and Extraintestinal Cancers: Mechanistic Insights and Microbiome-Targeted Interventions.
2026cited by 0position: contributordoi
Artificial Intelligence Analysis of Endoscopy Outperforms Conventional Endoscopic Scoring for Agreement With Symptoms and Quality of Life in a Phase 3 Ulcerative Colitis Trial.
2026cited by 0position: contributordoi
A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn's disease.
2025cited by 5position: contributordoi
Inflammation-Induced Th17 Cells Synergize with the Inflammation-Trained Microbiota to Mediate Host Resiliency Against Intestinal Injury.
2025cited by 2position: contributordoi
Why Symptoms Linger in Quiescent Crohn's Disease: Investigating the Impact of Sulfidogenic Microbes and Sulfur Metabolic Pathways.
2025cited by 2position: contributordoi
IL-15 Promotes Inflammatory Th17 Cells in the Intestine.
2025cited by 1position: contributordoi
A deeper quiet: Tofacitinib and the potential of endo-histologic remission.
2025cited by 0position: contributordoi
Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience
American Journal of Gastroenterology 2024cited by 47position: contributordoi
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024
Journal of the National Comprehensive Cancer Network 2024cited by 37position: middledoi
Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2Series.
2024cited by 15position: contributordoi
Factors Associated With Extraintestinal Manifestations of Inflammatory Bowel Disease in SPARC-IBD
Inflammatory Bowel Diseases 2023cited by 7position: middledoi
Nurturing the Gut, Moms with IBD and Their Babies.
2023cited by 0position: contributordoi
The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD).
2022cited by 43position: contributordoi
The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity.
2022cited by 4position: contributordoi
Mucolytic bacteria license pathobionts to acquire host-derived nutrients during dietary nutrient restriction
2022cited by 1position: contributordoi
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
2021cited by 97position: contributordoi
DUOX2 variants associate with preclinical disturbances in microbiota-immune homeostasis and increased inflammatory bowel disease risk
Journal of Clinical Investigation 2021cited by 79position: middledoi
Fully automated endoscopic disease activity assessment in ulcerative colitis.
2021cited by 77position: contributordoi
DUOX2 variants associate with preclinical disturbances in microbiota-immune homeostasis and increased inflammatory bowel disease risk.
2021cited by 66position: contributordoi
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
2021cited by 63position: contributordoi
A potential pathogenic association between periodontal disease and Crohn's disease.
2021cited by 56position: contributordoi
The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)
Inflammatory Bowel Diseases 2021cited by 54position: middledoi
Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance.
2021cited by 18position: contributordoi
PIR-B Regulates CD4<sup>+</sup> IL17a<sup>+</sup> T-Cell Survival and Restricts T-Cell-Dependent Intestinal Inflammatory Responses.
2021cited by 7position: contributordoi
Nutrient sensing.
2021cited by 1position: contributordoi
The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis.
2020cited by 494position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Ryan W. Stidham · Analysis Group (United States)13 papers (2019–2026) · 11 papers (2019–2026)Nobuhiko Kamada · Ann Arbor VA Medical Center10 papers (2019–2025) · 6 papers (2020–2025)Sho Kitamoto · University of Michigan5 papers (2020–2021)John Y. Kao · Université Bourgogne Franche-Comté5 papers (2019–2021) · 4 papers (2019–2021)Atsushi Hayashi · Robotics Research (United States)3 papers (2020–2021)Peter Higgins · Michigan Medicine3 papers (2019–2026) · 3 papers (2019–2026)Parakkal Deepak · South Asian University3 papers (2021–2025) · 3 papers (2019–2026)Akbar K. Waljee · Southwestern Medical Center3 papers (2019–2019)Vishal Sharma · South Asian University2 papers (2026–2026)Jeffrey A. Berinstein · Huron Gastro2 papers (2019–2024)Calen A. Steiner · Michigan Medicine2 papers (2019–2024)Jonathan L. Golob · Université Bourgogne Franche-Comté2 papers (2021–2025)Marc S. Piper · Trinity Health2 papers (2019–2019)Andres J Yarur · Medical College of Wisconsin2 papers (2022–2025) · 2 papers (2026–2026)